To test whether different doses of JMJD3 play a role in AML pathogenesis, we examined a possible association between the JMJD3 mRNA expression level and the overall survival in a cohort of AML patients from datasets of Verhaak and colleagues22. This evidence concerns the gene KDM6B and acute myeloid leukemia.